USD 7.71
(-4.76%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 251.45 Million USD | -47.36% |
2022 | 477.7 Million USD | 52.21% |
2021 | 313.83 Million USD | 309.4% |
2020 | 76.65 Million USD | 41.48% |
2019 | 54.18 Million USD | 0.0% |
2001 | 98.28 Million USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 37.94 Million USD | 9.18% |
2024 Q2 | 56.2 Million USD | 48.13% |
2023 Q3 | 55.43 Million USD | -31.2% |
2023 Q1 | 80.7 Million USD | -17.89% |
2023 FY | 251.45 Million USD | -47.36% |
2023 Q2 | 80.56 Million USD | -0.17% |
2023 Q4 | 34.75 Million USD | -37.3% |
2022 Q3 | 66.39 Million USD | -54.09% |
2022 FY | 477.7 Million USD | 52.21% |
2022 Q2 | 144.61 Million USD | -14.12% |
2022 Q1 | 168.4 Million USD | 13.41% |
2022 Q4 | 98.28 Million USD | 48.02% |
2021 FY | 313.83 Million USD | 309.4% |
2021 Q4 | 148.49 Million USD | 91.33% |
2021 Q3 | 77.61 Million USD | 77.86% |
2021 Q2 | 43.63 Million USD | -1.05% |
2021 Q1 | 44.09 Million USD | 37.55% |
2020 Q1 | 21.13 Million USD | 0.0% |
2020 FY | 76.65 Million USD | 41.48% |
2020 Q3 | 13.3 Million USD | 30.89% |
2020 Q4 | 32.05 Million USD | 141.0% |
2020 Q2 | 10.16 Million USD | -51.91% |
2019 FY | 54.18 Million USD | 0.0% |
2001 Q1 | 168.4 Million USD | 0.0% |
2001 Q3 | 66.39 Million USD | -54.09% |
2001 FY | 98.28 Million USD | 0.0% |
2001 Q2 | 144.61 Million USD | -14.12% |
Name | Revenue | Revenue Difference |
---|---|---|
ADC Therapeutics SA | 69.55 Million USD | -261.504% |
Alto Neuroscience, Inc. | - USD | -Infinity% |
Annovis Bio, Inc. | - USD | -Infinity% |
Biohaven Pharmaceutical Holding Company Ltd. | - USD | -Infinity% |
Nuvation Bio Inc. | - USD | -Infinity% |
Nuvation Bio Inc. | - USD | -Infinity% |
Arcus Biosciences, Inc. | 117 Million USD | -114.919% |
Zymeworks Inc. | 76.01 Million USD | -230.81% |